NCT05652686 - A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Biotech Hunter

Enrollment

203

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

August 31, 2028

Conditions

Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)Neuroendocrine Carcinomas (NEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

Interventions

DRUG

Peluntamig (PT217)

A bispecific antibody (bsAb) against DLL3 and CD47.

DRUG

Carboplatin + Etoposide

Administered per Standard of Care.

DRUG

Paclitaxel.

Administered per Standard of Care.

DRUG

Atezolizumab

Administered per Standard of Care.

Trial Locations (12)

21287

RECRUITING

Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore

22031

RECRUITING

NEXT Virginia, Fairfax

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

63108

RECRUITING

Washington University School of Medicine (Siteman Cancer Center), St Louis

73104

RECRUITING

Sarah Cannon Research Institute University of Oklahoma, Oklahoma City

77030

NOT_YET_RECRUITING

The University of Texas, MD Anderson Cancer Center, Houston

78229

RECRUITING

Mays Cancer Center / University of Texas, San Antonio, San Antonio

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

91010

RECRUITING

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte

97213

RECRUITING

Providence Portland Medical Center, Portland

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston